ALLR (Allarity Therapeutics) General and Admin. Expense: $6.11 Mil (TTM As of Mar. 2026)


ALLR Allarity Therapeutics Inc ALLR
24 GF Score
Price $1.30
! 2 Warning Signs
View Full Analysis

What is Allarity Therapeutics General and Admin. Expense?

Allarity Therapeutics ALLR +1.56% 24 General and Admin. Expense is $6.11 Mil as of Mar. 2026. GuruFocus rates ALLR with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Allarity Therapeutics's General and Admin. Expense for the three months ended in Mar. 2026 was $1.42 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $6.11 Mil.

Allarity Therapeutics General and Admin. Expense Related Terms

Allarity Therapeutics General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Allarity Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allarity Therapeutics General and Admin. Expense Chart

Allarity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial 12.36 9.96 10.03 11.44 6.32

Allarity Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.63 1.81 1.32 1.56 1.42
ALLR
24GF Score
Allarity Therapeutics Inc ALLR
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Allarity Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of $6.11 Mil mean?
Allarity Therapeutics (ALLR) has a General and Admin. Expense of $6.11 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Allarity Therapeutics and its competitors.
Is Allarity Therapeutics' General and Admin. Expense too high?
Allarity Therapeutics' current General and Admin. Expense is $6.11 Mil. Overall, Allarity Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Allarity Therapeutics' General and Admin. Expense compare to OTLC and MRKR?
Allarity Therapeutics' General and Admin. Expense of $6.11 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Allarity Therapeutics and its competitors. Allarity Therapeutics's current General and Admin. Expense is $6.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allarity Therapeutics stock overvalued right now?
Allarity Therapeutics (ALLR) has a current General and Admin. Expense of $6.11 Mil. The current General and Admin. Expense is $6.11 Mil. Allarity Therapeutics' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Allarity Therapeutics (ALLR), the current General and Admin. Expense is $6.11 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allarity Therapeutics Business Description

Address 123 East Tarpon Avenue, Tarpon Springs, FL, USA, 34689
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
24GF Score

Get the complete analysis for ALLR

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.30
Price